Fig. 3: In vivo efficacy of CT-P59 in the upper respiratory tract in an animal model.

Female ferrets (n = 6/group), and rhesus monkeys (three control; two 45 mg/kg; three 90 mg/kg) were challenged with 10^5.8 TCID₅₀/ml and 10^6.4 TCID₅₀ of SARS-CoV-2, respectively. Control (ferrets: 30 mg/kg of human IgG isotype and rhesus monkeys: vehicle) and CT-P59 (ferrets: 3, and 30 mg/kg, rhesus monkeys: 45, and 90 mg/kg) were administered intravenously after 24 h of virus inoculation, respectively. To compare the efficacy of CT-P59, remdesivir (18 mg/kg per ferret) was administered daily via oral gavage after 24 h of virus inoculation in ferrets for 5 days. To detect viral load in the upper respiratory tract, nasal wash specimens were collected from ferrets at 2, 4, and 6 dpi, and nose and throat swab specimens from monkeys were collected daily up to 6 dpi. Virus titers (TCID₅₀) were measured in nasal wash/swab and throat swabs specimens from each group of (a) ferrets and, c, d rhesus monkeys. The viral RNA copy numbers were measured in nasal washes from (b) ferrets. Viral titers and RNA copy numbers are shown as mean values + /− SEM and titers below the limit of detection are shown as 0.8 log₁₀TCID₅₀/ml or 0.3 log₁₀ viral RNA copies/ml (dashed lines). The asterisks and daggers indicate significance between the control and each group as determined by two-way ANOVA and subsequent Dunnett’s test. *P = 0.0001 and **P < 0.0001 (a); *P = 0.0456, **P = 0.0035, ***P = 0.0001, ****P < 0.0001, and ^†P = 0.0005 (b); *P = 0.0079 and **P < 0.0001 (c); and *P = 0.0021 (d).